CRSP icon

CRISPR Therapeutics
CRSP

Overview Fund Activity

155 hedge funds and large institutions have $631M invested in CRISPR Therapeutics in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 52 closing their positions.

Holders
155
Holders Change
-24
Holders Change %
-13.41%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
30
Increased
41
Reduced
44
Closed
52
Calls
$11.4M
Puts
$17.5M
Net Calls
-$6.11M
Net Calls Change
+$20.4M

Top Buyers

1
OTPPB
1
Ontario Teachers' Pension Plan Board
Ontario, Canada
$16.6M
2
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$17.6M
3
FCM
3
Farallon Capital Management
California
$35.7M
4
CS
4
Credit Suisse
Switzerland
$22.1M
5
CCP
5
Clough Capital Partners
Massachusetts
$14.7M

Top Sellers

1
Jennison Associates
1
Jennison Associates
New York
$0
2
O
2
OrbiMed
New York
$0
3
CC
3
Casdin Capital
New York
$0
4
EC
4
EcoR1 Capital
California
$5.97M
5
JPMorgan Chase & Co
5
JPMorgan Chase & Co
New York
$1.48M
Name Holding Trade Value Shares
Change 		Shares
Change %
IGGA
201
Iron Gate Global Advisors
Utah
– -$2K -70 Closed
APP
202
Avantax Planning Partners
Iowa
– -$2K -50 Closed
OWA
203
One Wealth Advisors
California
– -$2K -37 Closed
MIM
204
Monashee Investment Management
Massachusetts
– -$4.88M – –
5 6 7 8
9